MorphoSys AG at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everyone. I am James Quigley, European Pharma and Biotech analyst at Morgan Stanley. It is my pleasure to welcome you all to this session with MorphoSys. Today, we are joined by CEO, Jean-Paul Kress.
Just before we kick off, I need to read the disclosure statement. So for important disclosures, please Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So with that, over to Jean-Paul for a quick 2 minute intro set theme.
Thank you for having us. Great to be here. At MorphoSys, we are trying to change the standard of care in hematology oncology. We have transformed the company over the last 3 years to make sure that we have a late-stage pipeline with assets in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |